Acorn Bioventures
420 Lexington Avenue, Suite 2626, New York, NY, 10170, United States
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Neuron23 | Jun 2025Participated | $97 MSeries D | |
Neurosterix | Apr 2024Participated | $63 MSeries A | |
CG Oncology | Aug 2023Participated | $105 MOther Equity | |
OnKure Therapeutics | May 2023Participated | $54 MSeries C | |
Bicara Therapeutics | Mar 2023Participated | $108 MSeries B | |
CG Oncology | Nov 2022Participated | $120 MSeries E | |
Neuron23 | Apr 2022Participated | $100 MSeries C | |
ONK Therapeutics | Jan 2022Led | $22 MSeries A | |
Acrivon Therapeutics | Nov 2021Participated | $100 MSeries B | |
Eliem Therapeutics | May 2021Participated | $60 MSeries B | |
Neuron23 | Dec 2020Participated | $114 MSeries B | |
Q32 Bio | Nov 2020Led | $60 MSeries B | |
Neuron23 | Jun 2025Participated | $97 MSeries D | |
Neurosterix | Apr 2024Participated | $63 MSeries A | |
CG Oncology | Aug 2023Participated | $105 MOther Equity | |
OnKure Therapeutics | May 2023Participated | $54 MSeries C | |
Bicara Therapeutics | Mar 2023Participated | $108 MSeries B | |
CG Oncology | Nov 2022Participated | $120 MSeries E | |
Neuron23 | Apr 2022Participated | $100 MSeries C | |
ONK Therapeutics | Jan 2022Led | $22 MSeries A | |
Acrivon Therapeutics | Nov 2021Participated | $100 MSeries B | |
Eliem Therapeutics | May 2021Participated | $60 MSeries B | |
Neuron23 | Dec 2020Participated | $114 MSeries B | |
Q32 Bio | Nov 2020Led | $60 MSeries B |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 1 | 2 |
| Series B | 1 | 4 |
| Series C+ | 0 | 5 |
| Other Equity | 1 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jul '20 | 2 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 1 |
| Nov '20 | 1 |
| Dec '20 | 1 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 1 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 1 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 1 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 0 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 1 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 1 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 1 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 15 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 1 |
| $10M-$25M | 1 |
| $25M-$50M | 0 |
| $50M-$100M | 5 |
| $100M-$250M | 8 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 11 |
| Europe | 4 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Perceptive Advisors | 6 |
| RA Capital Management | 5 |
| Surveyor Capital | 4 |
| Ally Bridge Group | 3 |
| Cowen Healthcare Investments | 3 |
| Kleiner Perkins | 3 |
| Redmile Group | 3 |
| Westlake Village BioPartners | 3 |
| Atlas Venture | 2 |
| BVF Partners | 2 |
| Cormorant Asset Management | 2 |
| Decheng Capital | 2 |
| HBM Healthcare Investments | 2 |
| HBM Partners | 2 |
| Janus Henderson Investors | 2 |
| Longitude Capital | 2 |
| Malin Corporation | 2 |
| OrbiMed | 2 |
| Samsara BioCapital | 2 |
| SoftBank | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 3 | 20% |
| Participating | 12 | 80% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 1 | 33% |
| Co-led | 2 | 67% |
Team
Partner & Founder
Partner